Claritin ANDAs
This article was originally published in The Tan Sheet
Executive Summary
FDA has determined it may approve abbreviated new drug applications for Schering-Plough's Claritin Hives Relief Syrup (5 mg/5 mL loratadine) because the product "was not withdrawn from sale for reasons of safety or effectiveness," a notice in the Federal Register Feb. 2 states. Schering received approval for the product in November 2003 (1"The Tan Sheet" Nov. 24, 2003, p. 9). Although the firm sells a Hives Relief tablet, the syrup formulation was never marketed. The decision by the agency came in response to a February 2005 citizen petition submitted by Silarx Pharmaceuticals. The syrup will continue to be listed on the "Discontinued Product List" section of the Orange Book, FDA says...
You may also be interested in...
Claritin Hives Relief Approval Could Close Out Rx Product Line
Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19
Bayer Confident CureVac COVID Pact Will Be A Success
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
EMA Works On Defining Metadata From RWD Sources
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: